MXPA03004517A - Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis. - Google Patents
Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.Info
- Publication number
- MXPA03004517A MXPA03004517A MXPA03004517A MXPA03004517A MXPA03004517A MX PA03004517 A MXPA03004517 A MX PA03004517A MX PA03004517 A MXPA03004517 A MX PA03004517A MX PA03004517 A MXPA03004517 A MX PA03004517A MX PA03004517 A MXPA03004517 A MX PA03004517A
- Authority
- MX
- Mexico
- Prior art keywords
- atherosclerosis
- oxidized phospholipids
- prevention
- treatment
- compositions containing
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 3
- 150000003904 phospholipids Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan formas sinteticas novedosas de fosfolipidos oxidados eterificados y metodos de utilizar los mismos para prevenir y tratar la arteriosclerosis y otros padecimientos relacionados. Adicionalmente, tambien se proporcionan metodos para sintetizar los fosfolipidos oxidados eterificados y el uso de los mismos para prevenir y tratar la arteriosclerosis y otros padecimientos relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25257400P | 2000-11-24 | 2000-11-24 | |
PCT/IL2001/001080 WO2002041827A2 (en) | 2000-11-24 | 2001-11-22 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03004517A true MXPA03004517A (es) | 2004-03-26 |
Family
ID=22956589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03004517A MXPA03004517A (es) | 2000-11-24 | 2001-11-22 | Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis. |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1341543A4 (es) |
JP (3) | JP4162486B2 (es) |
KR (1) | KR100865142B1 (es) |
CN (1) | CN100577174C (es) |
AU (2) | AU1846102A (es) |
CA (1) | CA2429817C (es) |
IL (1) | IL156015A0 (es) |
MX (1) | MXPA03004517A (es) |
WO (1) | WO2002041827A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1846102A (en) * | 2000-11-24 | 2002-06-03 | Cardimmune Ltd | Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis |
US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
WO2004006910A1 (de) * | 2002-07-15 | 2004-01-22 | Norbert Leitinger | Lipidoxidationsprodukte zur hemmung von entzündungen |
AU2007200090B2 (en) * | 2004-07-09 | 2011-09-22 | Vascular Biogenics Ltd. | Improved Process for the Preparation of Oxidized Phospholipids |
WO2006006161A2 (en) * | 2004-07-09 | 2006-01-19 | Vascular Biogenics Ltd. | Improved process for the preparation of oxidized phospholipids |
US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
WO2009116750A2 (ko) * | 2008-03-17 | 2009-09-24 | 이화여자대학교 산학협력단 | 혈관 재협착방지 스텐트 코팅용 조성물 및 이를 이용해 제조된 스텐트 |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
US8815508B2 (en) | 2008-08-12 | 2014-08-26 | Zinfandel Pharmaceuticals, Inc. | Method of identifying disease risk factors |
EP2348864A4 (en) | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
EP2826369A3 (en) * | 2008-11-06 | 2015-03-18 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
JP2013516455A (ja) * | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Vb−201を用いた治療 |
SG191399A1 (en) | 2011-01-10 | 2013-08-30 | Zinfandel Pharmaceuticals Inc | Methods and drug products for treating alzheimer's disease |
MX357759B (es) | 2011-09-01 | 2018-07-24 | Vascular Biogenics Ltd | Formulaciones y formas de dosificacion de fosfolipidos oxidados. |
CA2876177C (en) * | 2012-06-11 | 2022-06-14 | The Cleveland Clinic Foundation | Treatment and prevention of cardiovascular disease and thrombosis |
WO2016084023A1 (en) | 2014-11-26 | 2016-06-02 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
CH642665A5 (en) | 1979-02-08 | 1984-04-30 | Rudolf Berchtold | Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides |
US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
DE3307925A1 (de) * | 1983-03-05 | 1984-09-06 | A. Nattermann & Cie GmbH, 5000 Köln | Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
US4614796A (en) * | 1983-03-25 | 1986-09-30 | Nippon Shinyaku Co., Ltd. | Liposome and method of manufacture therefor |
JPS60100544A (ja) * | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体,その製造方法及びその誘導体を含有する薬剤 |
JPS60104066A (ja) * | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
EP0225129B1 (en) * | 1985-11-29 | 1989-05-24 | Takeda Chemical Industries, Ltd. | Phospholipid derivatives, their production and use |
JPH01502584A (ja) * | 1986-03-24 | 1989-09-07 | ザ ユニバーシティー オブ シドニー | 抗原性物質 |
JPS6354386A (ja) * | 1986-08-26 | 1988-03-08 | Takeda Chem Ind Ltd | リン脂質およびその用途 |
JPH01258691A (ja) * | 1988-04-06 | 1989-10-16 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
ES2019552A6 (es) * | 1990-04-11 | 1991-06-16 | Menarini Lab | Procedimiento para la preparacion de glicerofosfolipidos. |
US5561052A (en) | 1992-06-18 | 1996-10-01 | Koike; Katsumasa | Process for detecting oxidized lipids and process for forming oxidized lipids |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5807884A (en) | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
DE69533545T2 (de) | 1994-01-31 | 2006-01-05 | Institute Of Cancer Research Royal Cancer Hospital | Faltende proteine |
AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
JP3364313B2 (ja) * | 1994-03-22 | 2003-01-08 | 株式会社トクヤマ | ポルフィリン/インジウム錯体及び陰イオン感応膜 |
US5660855A (en) * | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
US6156500A (en) | 1995-02-10 | 2000-12-05 | Millennium Pharmaceuticals, Inc. | Methods for the treatment and diagnosis of cardiovascular disease |
US6261597B1 (en) | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
US6034102A (en) | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
US6114395A (en) | 1996-11-15 | 2000-09-05 | Pfizer Inc. | Method of treating atherosclerosis |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
US5935577A (en) | 1998-01-23 | 1999-08-10 | Autoimmune Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
US5945308A (en) | 1998-04-03 | 1999-08-31 | Incyte Pharmaceuticals, Inc. | Human oxidized LDL receptor |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
US6701176B1 (en) | 1998-11-04 | 2004-03-02 | Johns Hopkins University School Of Medicine | Magnetic-resonance-guided imaging, electrophysiology, and ablation |
AU1846102A (en) * | 2000-11-24 | 2002-06-03 | Cardimmune Ltd | Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis |
-
2001
- 2001-11-22 AU AU1846102A patent/AU1846102A/xx active Pending
- 2001-11-22 MX MXPA03004517A patent/MXPA03004517A/es active IP Right Grant
- 2001-11-22 EP EP01997274A patent/EP1341543A4/en not_active Withdrawn
- 2001-11-22 JP JP2002544008A patent/JP4162486B2/ja not_active Expired - Lifetime
- 2001-11-22 CN CN01822215A patent/CN100577174C/zh not_active Expired - Lifetime
- 2001-11-22 CA CA2429817A patent/CA2429817C/en not_active Expired - Fee Related
- 2001-11-22 KR KR1020037006991A patent/KR100865142B1/ko not_active IP Right Cessation
- 2001-11-22 EP EP11189562A patent/EP2425841A1/en not_active Withdrawn
- 2001-11-22 WO PCT/IL2001/001080 patent/WO2002041827A2/en active Application Filing
- 2001-11-22 AU AU2002218461A patent/AU2002218461B2/en not_active Ceased
- 2001-11-22 IL IL15601501A patent/IL156015A0/xx active IP Right Grant
-
2008
- 2008-06-10 JP JP2008151301A patent/JP5001906B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-16 JP JP2012060309A patent/JP2012149075A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1529605A (zh) | 2004-09-15 |
AU2002218461B2 (en) | 2006-09-07 |
JP4162486B2 (ja) | 2008-10-08 |
KR20030077543A (ko) | 2003-10-01 |
EP1341543A2 (en) | 2003-09-10 |
JP5001906B2 (ja) | 2012-08-15 |
AU1846102A (en) | 2002-06-03 |
CA2429817C (en) | 2013-02-12 |
JP2008222726A (ja) | 2008-09-25 |
WO2002041827A3 (en) | 2002-10-10 |
EP2425841A1 (en) | 2012-03-07 |
CN100577174C (zh) | 2010-01-06 |
JP2004537498A (ja) | 2004-12-16 |
KR100865142B1 (ko) | 2008-10-24 |
CA2429817A1 (en) | 2002-05-30 |
WO2002041827A2 (en) | 2002-05-30 |
WO2002041827A9 (en) | 2003-05-30 |
EP1341543A4 (en) | 2009-09-02 |
JP2012149075A (ja) | 2012-08-09 |
IL156015A0 (en) | 2003-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03004517A (es) | Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis. | |
EP1445317A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
NO20013554D0 (no) | Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner | |
PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
PL349028A1 (en) | Cancer treatment composition and method using natural plant essential oils | |
YU19499A (sh) | Benzonaftiridini kao bronhijalni terapeutici | |
ZA200106160B (en) | Compositions and methods for treating cataracts. | |
PL338339A1 (en) | Novel derivatives of tetrazole | |
MXPA02001612A (es) | Composiciones anti-convulsivas transnasales y procedimiento modular. | |
AU1316000A (en) | Compositions and methods for treating benign prostatic hyperplasia using tocotrienols | |
WO2000004954A3 (de) | Neue urokinase-inhibitoren | |
WO2002016581A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
IL141686A0 (en) | Methods of treating hypertension and compositions for use therein | |
AU2002218461A1 (en) | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | |
WO2002016602A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
BG101109A (en) | Thiopyridyl compounds for controlling helicobacter bacteria | |
MXPA02009549A (es) | Imidazopiridinas triciclicas. | |
BG102770A (en) | New derivatives of carboxylic acids, their preparation and application | |
BG104292A (en) | Methods and compositions for the treatment of rheumatoid arthritis | |
MXPA02007903A (es) | Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres. | |
ZA991315B (en) | Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
PL314799A1 (en) | Application of dimeticone in treating constipations | |
AU2002213097A1 (en) | Processes and compositions for treating fabric | |
HK1049485A1 (en) | DithiepinoÄ6,5-BÜpyridines, and related compositions, methods of producing and uses. | |
AP2000001963A0 (en) | Paroxetine ascorbate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |